Through the deal, BioDuro has acquired Molecular Response's translational oncology research platform and its biobank of viable tumor specimens.

Among other projects, the company will make improvements to its internal bioinformatics pipeline and develop a 5,000-sample cohort for oncology research use.

Amgen will use BC Platforms' tools and services to study data in multiple indications, including cardiovascular and bone diseases, hematological malignancies, and other cancers.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The platform will be based on the company's BC|Rquest system for analyzing and viewing aggregated genomic and clinical data from multiple biobanks.

Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

Under the agreement MedStar will contribute to Indivumed’s biobank of annotated tumor and liquid biospecimen samples, and gain research access to this larger database.

TreeWAS provides a method for identifying gene variant-phenome associations in heterogenous biobank data without compromising phenotypic resolution.

The release has been accompanied by acute interest from the genomics community, which views the resource as a "game changer" for anyone working in human genetics.

The effort is already bearing fruit, as the team has been able to validate several variants known to be connected with adverse drug reactions.


The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.